>
NEW PAPER REVEALS HOW ANONYMOUS AGENTS ERASE YEARS OF VACCINE SAFETY AND...
72 Straight Hours Of Major Outages Doesn't Seem Like A "Coincidence" To Me
Strategy And The Endless Reinvention Of Nothing
Inside the 007 casting, including the mistake that cleared the way for Robert Pattinson...
SpaceX Just Caught Starship on Its FIRST Attempt!
Solid-State Cells Can Make The U.S. Competitive In Batteries Again: CEO
Jetson ONE personal eVTOL pod is about to go full sky patrol
America's INSANE BREAKTHROUGH Could Replace Septic Tanks Forever
Amazing DIY Building Material for Home & Yard - Inexpensive and Easy!
Researchers have discovered a massive deposit of hidden water...
Amazon's Ring Unveils Flying Drone And Robot To Patrol Homes And Businesses
Anthropic Strikes $3.4 Billion Off-Grid Power Agreement to Bypass U.S. Grids, Reports Say
The X-ray room just shrank to the size of a laptop
Gritt and MasTec partner to bring physical AI to solar construction sites

Over the past year, the gap between the super-rich and the rest of us has grown wider than ever before.
But the difference between ordinary people and billionaires might be more than just money. Some high net worth individuals have been looking into extending their lives far beyond the 70 or 80 years most of us might hope for.
Peter Thiel, for example, the billionaire co-founder of PayPal, has invested in a number medical research start-ups looking extending life expectancy though his Breakout Labs fund.
One of the companies longevity obsessive Thiel has bankrolled is Ambrosia.
Ambrosia is one of three outfits looking at experimental "vampire" blood transfusions that put the blood of young people into the lens of oldies.
According to commercial finance experts ABC Finance, the cost of the trials currently ranges from £6,000 to about £215,000.